A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
Price : $35 *
At a glance
- Drugs Cenderitide (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 25 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to lack of funds.
- 25 Jul 2017 Planned initiation date changed from 1 May 2017 to 30 Sep 2017.
- 30 Mar 2017 New trial record